A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Abroad (travel likely)RecruitingPHASE1

Conditions

Advanced Malignant Solid Neoplasm · RAS Mutation · Lung Cancer · Colon Cancer · Glioblastoma · Pancreatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California, United States
Sarah Cannon, SCRI Oncology Partners - Health One, Denver, Colorado, United States
Sarah Cannon, SCRI Oncology Partners, Nashville, Tennessee, United States

Study leads

Michael Mann, MD
Study Director
RasCal Therapeutics, Inc.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Advanced Solid Tumor · Metastatic Solid Tumor · Refractory Solid Tumor

Abroad (travel likely)RecruitingPHASE1

Sarasota, United States · Boston, United States

Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

Cancer · Advanced Cancer · Advanced Solid Tumor

Abroad (travel likely)Recruiting

Chicago, United States

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Cancer · Tumor, Solid · Malignant Neoplasm

Abroad (travel likely)RecruitingPHASE1, PHASE2

Austin, United States · Irving, United States

CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

Lung Cancer · Gastric Cancer · Colon Cancer

Abroad (travel likely)RecruitingPHASE1

Hefei, China